Nucleic Acid Preparations Identify Norovirus and Mycoplasma pneumonia
|
By LabMedica International staff writers Posted on 15 Oct 2013 |

Image: DiaSorin's LIAISON IXT for the purification of nucleic acids (Photo courtesy of Diasorin).
Extraction kits provide high yield, high purity nucleic acid preparations for sensitive and accurate molecular identification of Norovirus and Mycoplasma pneumonia.
Magnetic bead technology extraction kits concentrates target microorganisms from a variety of sample matrices, including urine, sputum, culture, and swabs, and then provides a purified nucleic acid extraction for downstream molecular analysis. No enzymatic pretreatment or prior heat treatment is required.
The DiaSorin (Saluggia, Italy) BUGS’n Beads nucleic acid extraction kits, for use with the automated DiaSorin LIAISON IXT/Arrow instruments, provide a highly purified nucleic acid preparation from patient samples for sensitive and accurate molecular confirmation of these microorganisms.
Outbreaks of Norovirus, also known as winter vomiting disease, can spread quickly in certain semiclosed environments and frequently cause ward closures in hospitals during the winter months. Human noroviruses cannot be grown in cell culture and so diagnostic methods focus on the detection of viral RNA or antigen.
Mycoplasma pneumonia is a common cause of atypical pneumonia. Since other, less common etiological agents exist, which require a different course of treatment, identification of bacterial DNA in clinical samples has become increasingly important in establishing the cause of atypical pneumonia so that the optimal directed therapy can be provided for patients.
During winter, clinical laboratories experience an increase in test requests for certain seasonal pathogens such as Norovirus and Mycoplasma pneumonia. The DiaSorin nucleic acid extraction kits, for use with the automated DiaSorin LIAISON IXT/Arrow instruments, provide a highly purified nucleic acid preparation from patient samples for sensitive and accurate molecular confirmation of these microorganisms.
DiaSorin BUGS’n Beads can be used for the extraction of nucleic acid from a variety of pathogens, including Mycobacterium tuberculosis, Enterovirus, MRSA, Norovirus, Escherichia coli, Legionella, Mycoplasma pneumonia, Chlamydia pneumonia, and Helicobacter pylori.
In addition to BUGS’n Beads, DiaSorin nucleic acid extraction kits are available for the extraction of RNA or DNA, the extraction of DNA from stool and blood samples, and cell separation.
Related Links:
DiaSorin
Magnetic bead technology extraction kits concentrates target microorganisms from a variety of sample matrices, including urine, sputum, culture, and swabs, and then provides a purified nucleic acid extraction for downstream molecular analysis. No enzymatic pretreatment or prior heat treatment is required.
The DiaSorin (Saluggia, Italy) BUGS’n Beads nucleic acid extraction kits, for use with the automated DiaSorin LIAISON IXT/Arrow instruments, provide a highly purified nucleic acid preparation from patient samples for sensitive and accurate molecular confirmation of these microorganisms.
Outbreaks of Norovirus, also known as winter vomiting disease, can spread quickly in certain semiclosed environments and frequently cause ward closures in hospitals during the winter months. Human noroviruses cannot be grown in cell culture and so diagnostic methods focus on the detection of viral RNA or antigen.
Mycoplasma pneumonia is a common cause of atypical pneumonia. Since other, less common etiological agents exist, which require a different course of treatment, identification of bacterial DNA in clinical samples has become increasingly important in establishing the cause of atypical pneumonia so that the optimal directed therapy can be provided for patients.
During winter, clinical laboratories experience an increase in test requests for certain seasonal pathogens such as Norovirus and Mycoplasma pneumonia. The DiaSorin nucleic acid extraction kits, for use with the automated DiaSorin LIAISON IXT/Arrow instruments, provide a highly purified nucleic acid preparation from patient samples for sensitive and accurate molecular confirmation of these microorganisms.
DiaSorin BUGS’n Beads can be used for the extraction of nucleic acid from a variety of pathogens, including Mycobacterium tuberculosis, Enterovirus, MRSA, Norovirus, Escherichia coli, Legionella, Mycoplasma pneumonia, Chlamydia pneumonia, and Helicobacter pylori.
In addition to BUGS’n Beads, DiaSorin nucleic acid extraction kits are available for the extraction of RNA or DNA, the extraction of DNA from stool and blood samples, and cell separation.
Related Links:
DiaSorin
Latest Technology News
- Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
- Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
- New Platform Captures Extracellular Vesicles for Early Cancer Detection
- Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
- AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
- Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
- Noninvasive Sputum Test Detects Early Lung Cancer
- New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
- Rapid Biosensor Detects Drug Sensitivity in Breast Tumors
- Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
- Online Tool Supports Family Screening for Inherited Cancer Risk
- Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
- New Electronic Pipette Enhances Workflows with Touchscreen Control
- AI Model Outperforms Clinicians in Rare Disease Detection
- AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
- Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
Channels
Clinical Chemistry
view channel
Noninvasive Urine Test May Support Earlier Diagnosis of Psychiatric Disorders
Delays in diagnosing serious psychiatric conditions can leave patients without timely support and complicate treatment planning. For bipolar disorder, average time to diagnosis can exceed nine years, and... Read moreAt-Home Blood and Cognitive Tests Support Dementia Risk Stratification
Dementia places a substantial burden on patients and health systems, and identifying individuals at elevated risk remains difficult at scale. In the UK, almost a million people are estimated to be living... Read moreMolecular Diagnostics
view channel
Emerging Biomarkers Advance Early Detection of MASLD and Liver Cancer Risk
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects about 30% of people worldwide and can advance to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and... Read more
Patented Isothermal Amplification Chemistry Advances Decentralized Testing
Molecular diagnostics offer high sensitivity for pathogen detection but typically rely on thermal cycling and specialized instruments, limiting their use outside centralized laboratories.... Read more
Finger-Prick Blood Test Aids Early Tuberculosis Detection and Risk Stratification
Household contacts of people with tuberculosis face an estimated 2% risk of developing disease, yet most are asymptomatic at the time of screening. Early-stage cases are often missed because symptom checks... Read more
Urine Test Beats MRI in Identifying Prostate Cancer Upgrading During Active Surveillance
Active surveillance is common for men with low-risk prostate cancer, yet deciding when to repeat biopsy remains challenging. Prostate-specific antigen (PSA) testing and magnetic resonance imaging (MRI)... Read moreHematology
view channel
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read moreImmunology
view channel
Biomarkers and Molecular Testing Advance Precision Allergy Care
Allergic diseases often present with similar symptoms but can be driven by distinct biological mechanisms, making standardized care inefficient for many patients. Historically, individuals with pollen... Read more
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreTechnology
view channel
Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
Latent tuberculosis remains a substantial testing workload for clinical laboratories as screening programs expand. Despite this growth, only about 40% of testing has shifted from traditional skin tests... Read more
Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read moreIndustry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more








